TELA Bio reported $19 million revenue in Q3 2026, down 8% year-over-year but with an 18% increase in international sales. The company reduced its operating loss by 21% sequentially and improved adjusted EBITDA loss by 55%, driven by a strategic cost reduction plan saving $17 million annually. TELA Bio regained Nasdaq compliance and received FDA clearance for a new soft tissue scaffold product. The company aims to return to growth, supported by clinical data and market share gains in hernia repair products, with a cash runway extended into 2028.
TELA Bio's Q3 2026 financial results provide context for readers, with Pluang's health sector market snapshot as of Nov 11, 2026 04:02 WIB showing 52 of 150 US health stocks rose while 97 fell. Notable movers include RXRX at USD 3.56 with a 1-day change of -6.44% and 100% buy order activity, NVAX at USD 10.21 down 6.24% with 100% sell order activity, and BRKR at USD 62.40 down 6.22%. The most notable figure is the 100% buy order activity for RXRX.
Cannabis Strategic Ventures has finalized its change of control with Scopien Technologies, an AI platform company, which now holds voting control through preferred stock. The company has appointed new leadership, including CEO Zameer Mulla, and plans...
Star Bulk Carriers Corp. has published its 2025 Environmental, Social and Governance (ESG) Report, its eighth annual report detailing the company's sustainability strategy, performance, and future objectives. The report, guided by the ESG Committee, ...
Auburn National Bancorporation, Inc. announced a quarterly cash dividend of $0.27 per share, payable on December 28, 2026, to shareholders recorded by December 10, 2026. The company is the parent of AuburnBank, an Alabama state-chartered bank with ab...
OpenTable's 2027 Quebec dining trends report shows a 9% increase in restaurant bookings, with 65% of Quebecers planning to dine out as much or more in 2027. Consumers prioritize value, local favorites, and meaningful experiences, often celebrating sm...
Pepeto's crypto presale is close to selling out, having raised $11.29 million with over 43,000 holders, driven by its fee-free trading platform and AI contract checks. Meanwhile, XRP's price has dropped to $1.11, down 72% from its peak, but analysts ...
